Directorate Change

In brief · summary, not quotable

Dr Trevor Nicholls retiring as non-executive director; Mark Goldberg assumes Remuneration Committee Chair.

Full announcement

Select text to share a quote on X · sign in to keep highlights & notes in your AVCT notes

LONDON and PHILADELPHIA - April 29, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces that Dr. Trevor Nicholls, one of the Group's non-executive directors, is retiring from the Board with effect from April 30, 2025.

Mark Goldberg will take over as the Board's Chair of the Remuneration Committee

Shaun Chilton, non-executive Chairman commented:

"On behalf of the Avacta Board, I would like to thank Trevor for his valued contribution and dedication to the Company since his appointment in 2013 and wish him all the best for the future.

"As Avacta transitions to a pure-play biotechnology company, we have initiated the process of appointing an independent non-executive director with relevant international commercial experience and expertise. A further announcement will be made in due course."

Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.